The primary objective ofthe Biostatistics Core is to contribute to the science and operation ofthe program project by participating fully in its activities as it has forthe preparation of this application. This includes assistance and direction in experimental design, quality control, data collection and management, and statistical data analysis through consultation and collaboration. The team that helps prepare the application and will provide biostatistical supports for this program project consists of the following statisticians from the University of Minnesota and the Masonic Cancer Center: Chap Le (Core Director), Xianghua Luo, Todd DeFor, Yan Zhang, and Flora Fan, an expert in Computational Biology. Together the team from the University of Minnesota is responsible for Project 1, SA2, Project 2, SA1-3, and Project 3, SA2. This team is strengthened with the addition ofthe team from the Medical College of Wisconsin and CIBMTR led by John Klein, PhD (co-Director) and Tao Wang, a statistical geneticist. They wHI be assisted by Alexis Dye, MS a statistical programmer. The team from the Medical College of Wisconsin is responsible for Project 1, SA1 and Project 3, SA1. The assignment of biostatistician support is logical and based on whether the data is collected and stored at the University of Minnesota or transplant data through the National Marrow Donor Program and the CIBMTR at the Medical College of Wisiconsin.
The Program Project grant includes a number of clinical trials and research studies that require biostatical support for definitive analysis. This Core contains Faculty and staff at the University of Minnesota for prospective clinical trials and basic research study support. Faculty and staff from the CIBMTR are also included because they curate and are responsible for the unrelated transplant donor data.
|Cichocki, Frank; Verneris, Michael R; Cooley, Sarah et al. (2016) The Past, Present, and Future of NK Cells in Hematopoietic Cell Transplantation and Adoptive Transfer. Curr Top Microbiol Immunol 395:225-43|
|He, F; Warlick, E; Miller, J S et al. (2016) Lymphodepleting chemotherapy with donor lymphocyte infusion post-allogeneic HCT for hematological malignancies is associated with severe, but therapy-responsive aGvHD. Bone Marrow Transplant 51:1107-12|
|Weisdorf, Daniel (2016) The role of second transplants for leukemia. Best Pract Res Clin Haematol 29:359-364|
|Sarhan, Dhifaf; Cichocki, Frank; Zhang, Bin et al. (2016) Adaptive NK Cells with Low TIGIT Expression Are Inherently Resistant to Myeloid-Derived Suppressor Cells. Cancer Res 76:5696-5706|
|Felices, Martin; Miller, Jeffrey S (2016) Targeting KIR Blockade in Multiple Myeloma: Trouble in Checkpoint Paradise? Clin Cancer Res 22:5161-5163|
|Schmohl, Joerg U; Felices, Martin; Taras, Elizabeth et al. (2016) Enhanced ADCC and NK Cell Activation of an Anticarcinoma Bispecific Antibody by Genetic Insertion of a Modified IL-15 Cross-linker. Mol Ther 24:1312-22|
|Horowitz, Amir; Guethlein, Lisbeth A; Nemat-Gorgani, Neda et al. (2015) Regulation of Adaptive NK Cells and CD8 T Cells by HLA-C Correlates with Allogeneic Hematopoietic Cell Transplantation and with Cytomegalovirus Reactivation. J Immunol 195:4524-36|
|Holtan, Shernan G; Verneris, Michael R; Schultz, Kirk R et al. (2015) Circulating angiogenic factors associated with response and survival in patients with acute graft-versus-host disease: results from Blood and Marrow Transplant Clinical Trials Network 0302 and 0802. Biol Blood Marrow Transplant 21:1029-36|
|Holtan, Shernan G; DeFor, Todd E; Lazaryan, Aleksandr et al. (2015) Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation. Blood 125:1333-8|
|Schlums, Heinrich; Cichocki, Frank; Tesi, Bianca et al. (2015) Cytomegalovirus infection drives adaptive epigenetic diversification of NK cells with altered signaling and effector function. Immunity 42:443-56|
Showing the most recent 10 out of 74 publications